HCA
FATE icon

Harbor Capital Advisors’s Fate Therapeutics FATE Stock Holding History

Harbor Capital Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,375
Closed -$142K – 740
2024
Q1 		$142K Buy
19,375
+3,844
+25% +$23.8K 0.02% 681
2023
Q4 		$58.1K Buy
15,531
+725
+5% +$1.71K 0.01% 430
2023
Q3 		$31.4K Buy
14,806
+2,678
+22% +$8.87K 0.01% 442
2023
Q2 		$57.7K Buy
12,128
+1,132
+10% +$6.25K 0.01% 481
2023
Q1 		$62.7K Buy
10,996
+82
+0.8% +$495 0.02% 242
2022
Q4 		$110K Sell
10,914
-232
-2% -$4.36K 0.11% 84
2022
Q3 		$250K Sell
11,146
-306
-3% -$8.84K 0.23% 79
2022
Q2 		$284K Sell
11,452
-1,256
-10% -$34.7K 0.22% 77
2022
Q1 		$493K Sell
12,708
-1,869
-13% -$72.4K 0.23% 79
2021
Q4 		$853K Buy
+14,577
New +$826K 0.31% 79

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Harbor Capital Advisors's FATE Position: Q2 2024 in Review

Harbor Capital Advisors sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 19,375 shares — an estimated $142K sold.

Harbor Capital Advisors first reported a position in FATE in Q4 2021 and held it in 10 quarters. The position peaked at $853K in Q4 2021. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Harbor Capital Advisors reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Harbor Capital Advisors sold 19,375 Fate Therapeutics shares in Q2 2024, an estimated $142K.
  • Harbor Capital Advisors first reported a position in Fate Therapeutics in Q4 2021 and held it in 10 quarters.
  • Harbor Capital Advisors's Fate Therapeutics position peaked at $853K in Q4 2021.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Harbor Capital Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.